|
US2671750A
(en)
|
1950-09-19 |
1954-03-09 |
Merck & Co Inc |
Stable noncaking aqueous suspension of cortisone acetate and method of preparing the same
|
|
US2830083A
(en)
|
1953-04-29 |
1958-04-08 |
Allied Chem & Dye Corp |
Production of aryloxy aliphatic carboxylic acids
|
|
DK270278A
(da)
|
1977-06-20 |
1978-12-21 |
Krogsgaard Larsen P |
Cycliske aminosyrer
|
|
DE3013839A1
(de)
|
1979-04-13 |
1980-10-30 |
Freunt Ind Co Ltd |
Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
|
|
US4362731A
(en)
|
1980-09-01 |
1982-12-07 |
Sandoz Ltd. |
Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
|
|
US4353910A
(en)
|
1981-11-27 |
1982-10-12 |
Kefalas A/S |
Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
|
|
CA1282405C
(en)
|
1984-05-21 |
1991-04-02 |
Michael R. Violante |
Method for making uniformly sized particles from water-insoluble organic compounds
|
|
US4826689A
(en)
|
1984-05-21 |
1989-05-02 |
University Of Rochester |
Method for making uniformly sized particles from water-insoluble organic compounds
|
|
US4783484A
(en)
|
1984-10-05 |
1988-11-08 |
University Of Rochester |
Particulate composition and use thereof as antimicrobial agent
|
|
US5340590A
(en)
|
1987-06-25 |
1994-08-23 |
Alza Corporation |
Delivery system with bilayer osmotic engine
|
|
US5391381A
(en)
|
1987-06-25 |
1995-02-21 |
Alza Corporation |
Dispenser capable of delivering plurality of drug units
|
|
JP2749409B2
(ja)
|
1987-11-17 |
1998-05-13 |
ローベルト ボツシユ ゲゼルシヤフト ミツト ベシユレンクテル ハフツング |
車輪センサにより検出された車両車輪回転速度の補正方法
|
|
US5133974A
(en)
|
1989-05-05 |
1992-07-28 |
Kv Pharmaceutical Company |
Extended release pharmaceutical formulations
|
|
DK469989D0
(da)
|
1989-09-22 |
1989-09-22 |
Bukh Meditec |
Farmaceutisk praeparat
|
|
DK546289D0
(da)
|
1989-11-02 |
1989-11-02 |
Danochemo As |
Carotenoidpulvere
|
|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
|
US5376645A
(en)
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
|
US5201756A
(en)
|
1990-06-20 |
1993-04-13 |
Danforth Biomedical, Inc. |
Radially-expandable tubular elements for use in the construction of medical devices
|
|
US5399363A
(en)
|
1991-01-25 |
1995-03-21 |
Eastman Kodak Company |
Surface modified anticancer nanoparticles
|
|
US5145684A
(en)
|
1991-01-25 |
1992-09-08 |
Sterling Drug Inc. |
Surface modified drug nanoparticles
|
|
MX9201782A
(es)
|
1991-04-19 |
1992-10-01 |
Sandoz Ag |
Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
|
|
AU2317592A
(en)
|
1991-07-05 |
1993-02-11 |
University Of Rochester |
Ultrasmall non-aggregated porous particles entrapping gas-bubbles
|
|
US5478577A
(en)
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
|
US5223265A
(en)
|
1992-01-10 |
1993-06-29 |
Alza Corporation |
Osmotic device with delayed activation of drug delivery
|
|
US5308348A
(en)
|
1992-02-18 |
1994-05-03 |
Alza Corporation |
Delivery devices with pulsatile effect
|
|
US5209746A
(en)
|
1992-02-18 |
1993-05-11 |
Alza Corporation |
Osmotically driven delivery devices with pulsatile effect
|
|
US5456679A
(en)
|
1992-02-18 |
1995-10-10 |
Alza Corporation |
Delivery devices with pulsatile effect
|
|
US5221278A
(en)
|
1992-03-12 |
1993-06-22 |
Alza Corporation |
Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
|
|
US5260068A
(en)
|
1992-05-04 |
1993-11-09 |
Anda Sr Pharmaceuticals Inc. |
Multiparticulate pulsatile drug delivery system
|
|
US5356476A
(en)
|
1992-06-15 |
1994-10-18 |
Materials Research Corporation |
Semiconductor wafer processing method and apparatus with heat and gas flow control
|
|
NZ248813A
(en)
|
1992-11-25 |
1995-06-27 |
Eastman Kodak Co |
Polymeric grinding media used in grinding pharmaceutical substances
|
|
US5260069A
(en)
|
1992-11-27 |
1993-11-09 |
Anda Sr Pharmaceuticals Inc. |
Pulsatile particles drug delivery system
|
|
US5346702A
(en)
|
1992-12-04 |
1994-09-13 |
Sterling Winthrop Inc. |
Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
|
|
US5298262A
(en)
|
1992-12-04 |
1994-03-29 |
Sterling Winthrop Inc. |
Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
|
|
US5336507A
(en)
|
1992-12-11 |
1994-08-09 |
Sterling Winthrop Inc. |
Use of charged phospholipids to reduce nanoparticle aggregation
|
|
US5429824A
(en)
|
1992-12-15 |
1995-07-04 |
Eastman Kodak Company |
Use of tyloxapole as a nanoparticle stabilizer and dispersant
|
|
US5352459A
(en)
|
1992-12-16 |
1994-10-04 |
Sterling Winthrop Inc. |
Use of purified surface modifiers to prevent particle aggregation during sterilization
|
|
US6280771B1
(en)
|
1997-02-20 |
2001-08-28 |
Therics, Inc. |
Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof
|
|
CA2186750C
(en)
|
1994-03-30 |
2008-08-05 |
Jens Hansen |
Use of fatty acid esters as bioadhesive substances
|
|
TW384224B
(en)
|
1994-05-25 |
2000-03-11 |
Nano Sys Llc |
Method of preparing submicron particles of a therapeutic or diagnostic agent
|
|
US5718388A
(en)
|
1994-05-25 |
1998-02-17 |
Eastman Kodak |
Continuous method of grinding pharmaceutical substances
|
|
NZ288144A
(en)
|
1994-06-22 |
1998-12-23 |
Unasco Pty |
Active agent sustained release capsule: fluid expandable layers and active agent layers
|
|
US5556847A
(en)
|
1994-10-27 |
1996-09-17 |
Duquesne University Of The Holy Ghost |
Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
|
|
US5628981A
(en)
|
1994-12-30 |
1997-05-13 |
Nano Systems L.L.C. |
Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
|
|
US5560932A
(en)
|
1995-01-10 |
1996-10-01 |
Nano Systems L.L.C. |
Microprecipitation of nanoparticulate pharmaceutical agents
|
|
US5665331A
(en)
|
1995-01-10 |
1997-09-09 |
Nanosystems L.L.C. |
Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
|
|
US5662883A
(en)
|
1995-01-10 |
1997-09-02 |
Nanosystems L.L.C. |
Microprecipitation of micro-nanoparticulate pharmaceutical agents
|
|
US5534270A
(en)
|
1995-02-09 |
1996-07-09 |
Nanosystems Llc |
Method of preparing stable drug nanoparticles
|
|
US5573783A
(en)
|
1995-02-13 |
1996-11-12 |
Nano Systems L.L.C. |
Redispersible nanoparticulate film matrices with protective overcoats
|
|
US5510118A
(en)
|
1995-02-14 |
1996-04-23 |
Nanosystems Llc |
Process for preparing therapeutic compositions containing nanoparticles
|
|
US5543133A
(en)
|
1995-02-14 |
1996-08-06 |
Nanosystems L.L.C. |
Process of preparing x-ray contrast compositions containing nanoparticles
|
|
ATE274341T1
(de)
|
1995-02-24 |
2004-09-15 |
Elan Pharma Int Ltd |
Nanopartikel-dispersionen enthaltende aerosole
|
|
DE19525598C2
(de)
|
1995-07-13 |
1997-09-25 |
Max Planck Gesellschaft |
Schlafmittel
|
|
US5888996A
(en)
|
1995-07-26 |
1999-03-30 |
Trustees Of Boston University |
Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
|
|
US5629277A
(en)
|
1995-10-04 |
1997-05-13 |
William L. Brown |
Paint removing composition
|
|
US5840329A
(en)
|
1997-05-15 |
1998-11-24 |
Bioadvances Llc |
Pulsatile drug delivery system
|
|
GB9711643D0
(en)
|
1997-06-05 |
1997-07-30 |
Janssen Pharmaceutica Nv |
Glass thermoplastic systems
|
|
WO1998057648A1
(en)
|
1997-06-16 |
1998-12-23 |
Vertex Pharmaceuticals Incorporated |
Methods of increasing the bioavailability of stable crystal polymorphs of a compound
|
|
DE69804832T2
(de)
|
1997-10-08 |
2002-11-07 |
Sepracor Inc., Marlborough |
Dosierungsform zur verabreichung von aerosolen
|
|
US6607751B1
(en)
|
1997-10-10 |
2003-08-19 |
Intellipharamaceutics Corp. |
Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
|
|
US5945123A
(en)
|
1998-04-02 |
1999-08-31 |
K-V Pharmaceutical Company |
Maximizing effectiveness of substances used to improve health and well being
|
|
US8293277B2
(en)
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
|
CA2653839A1
(en)
|
1998-11-02 |
2000-05-11 |
John G. Devane |
Multiparticulate modified release composition
|
|
US6375986B1
(en)
|
2000-09-21 |
2002-04-23 |
Elan Pharma International Ltd. |
Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
|
|
US6969529B2
(en)
|
2000-09-21 |
2005-11-29 |
Elan Pharma International Ltd. |
Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
|
|
US6428814B1
(en)
|
1999-10-08 |
2002-08-06 |
Elan Pharma International Ltd. |
Bioadhesive nanoparticulate compositions having cationic surface stabilizers
|
|
US6039979A
(en)
|
1999-01-13 |
2000-03-21 |
Laboratoires Prographarm |
Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation
|
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
US6267989B1
(en)
|
1999-03-08 |
2001-07-31 |
Klan Pharma International Ltd. |
Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
|
|
US6423746B1
(en)
|
1999-07-03 |
2002-07-23 |
The William M. Yarbrough Foundation |
Urushiol induced contact dermatitis and method of use
|
|
ATE297196T1
(de)
|
1999-12-20 |
2005-06-15 |
Nicholas J Kerkhof |
Verfahren zur herstellung von nanometer partikeln durch fliessbett- sprühtrocknung
|
|
US6689378B1
(en)
|
1999-12-28 |
2004-02-10 |
Kimberly-Clark Worldwide, Inc. |
Cyclodextrins covalently bound to polysaccharides
|
|
US6627223B2
(en)
|
2000-02-11 |
2003-09-30 |
Eurand Pharmaceuticals Ltd. |
Timed pulsatile drug delivery systems
|
|
US6316029B1
(en)
|
2000-05-18 |
2001-11-13 |
Flak Pharma International, Ltd. |
Rapidly disintegrating solid oral dosage form
|
|
US7198795B2
(en)
|
2000-09-21 |
2007-04-03 |
Elan Pharma International Ltd. |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
|
|
US8551526B2
(en)
|
2000-11-03 |
2013-10-08 |
Board Of Regents, The University Of Texas System |
Preparation of drug particles using evaporation precipitation into aqueous solutions
|
|
AR031473A1
(es)
*
|
2000-11-20 |
2003-09-24 |
Lundbeck & Co As H |
Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
|
|
US6976647B2
(en)
|
2001-06-05 |
2005-12-20 |
Elan Pharma International, Limited |
System and method for milling materials
|
|
US20030054042A1
(en)
|
2001-09-14 |
2003-03-20 |
Elaine Liversidge |
Stabilization of chemical compounds using nanoparticulate formulations
|
|
ATE371442T1
(de)
|
2001-10-12 |
2007-09-15 |
Elan Pharma Int Ltd |
Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
|
|
UA76810C2
(uk)
|
2001-12-10 |
2006-09-15 |
Мерк Енд Ко., Інк. |
Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
|
|
US20030129242A1
(en)
|
2002-01-04 |
2003-07-10 |
Bosch H. William |
Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
|
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
|
WO2003080023A2
(en)
|
2002-03-20 |
2003-10-02 |
Elan Pharma International Limited |
Fast dissolving dosage forms having reduced friability
|
|
US20040105889A1
(en)
|
2002-12-03 |
2004-06-03 |
Elan Pharma International Limited |
Low viscosity liquid dosage forms
|
|
JP2006501148A
(ja)
|
2002-05-03 |
2006-01-12 |
チルドレンズ ホスピタル メディカル センター |
皮膚の清浄化及び他の用途のためのシミュレートされた胎脂組成物
|
|
WO2004006959A1
(en)
|
2002-07-16 |
2004-01-22 |
Elan Pharma International, Ltd |
Liquid dosage compositions of stable nanoparticulate active agents
|
|
JP4729306B2
(ja)
|
2002-08-20 |
2011-07-20 |
ブリストル−マイヤーズ スクイブ カンパニー |
アリピプラゾール錯体の製剤と方法
|
|
DK1553927T3
(da)
|
2002-09-11 |
2011-01-31 |
Elan Pharma Int Ltd |
Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
|
|
EP1572164A2
(en)
|
2002-12-18 |
2005-09-14 |
Pain Therapeutics, Inc. |
Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
|
|
EP1663218A1
(en)
*
|
2003-09-10 |
2006-06-07 |
MERCK SHARP & DOHME LTD. |
Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
|
|
US20050181050A1
(en)
|
2004-01-28 |
2005-08-18 |
Collegium Pharmaceutical, Inc. |
Dosage forms using drug-loaded ion exchange resins
|
|
GB0402118D0
(en)
*
|
2004-01-30 |
2004-03-03 |
Merck Sharp & Dohme |
Polymorphic forms of a GABAA agonist
|
|
US20050226927A1
(en)
|
2004-04-02 |
2005-10-13 |
Impax Laboratories, Inc. |
Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
|
|
CA2561883A1
(en)
|
2004-04-02 |
2005-10-13 |
H. Lundbeck A/S |
Treatment of impaired respiratory function with gaboxadol
|
|
US7427601B2
(en)
*
|
2004-06-24 |
2008-09-23 |
Schwarz Pharma Ag |
Method for treating tremor
|
|
EP1771158A4
(en)
|
2004-07-02 |
2008-03-12 |
Advancis Pharmaceutical Corp |
TABLET FOR PULSE DISTRIBUTION
|
|
GB0417558D0
(en)
|
2004-08-06 |
2004-09-08 |
Merck Sharp & Dohme |
Novel combination therapy
|
|
US8604011B2
(en)
|
2004-09-27 |
2013-12-10 |
The Regents Of The University Of California |
Therapy for treatment of chronic degenerative brain diseases and nervous system injury
|
|
CN101180038A
(zh)
|
2005-03-23 |
2008-05-14 |
伊兰制药国际有限公司 |
纳米颗粒皮质类固醇和抗组胺药制剂
|
|
WO2006118897A1
(en)
*
|
2005-04-29 |
2006-11-09 |
H.Lundbeck A/S |
Acid and base salt forms of gaboxadol
|
|
DE102005020882A1
(de)
|
2005-05-04 |
2006-11-09 |
Dömling, Alexander, Dr. |
Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
|
|
EP1942879A1
(en)
|
2005-10-31 |
2008-07-16 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
US20110046090A1
(en)
|
2005-10-31 |
2011-02-24 |
Braincells Inc. |
Modulation of neurogenesis with gaba agents and gaba analogs
|
|
MX2008006888A
(es)
|
2005-11-28 |
2008-09-30 |
Marinus Pharmaceuticals |
Formulas y metodos para la manufactura y uso de la ganaxolona.
|
|
RS55585B1
(sr)
|
2006-11-22 |
2017-06-30 |
Clinical Research Associates LLC |
Postupci za lečenje daunovog sindroma, krhkog x sindroma i autizma
|
|
AU2007325628A1
(en)
|
2006-11-28 |
2008-06-05 |
Marinus Pharmaceuticals |
Nanoparticulate formulations and methods for the making and use thereof
|
|
TW200920358A
(en)
|
2007-08-13 |
2009-05-16 |
Lundbeck & Co As H |
Method of treating stress-mediated depression
|
|
KR100929920B1
(ko)
|
2007-09-05 |
2009-12-04 |
주식회사 마크로케어 |
사이클로덱스트린 및 이의 유도체에 소수성 생리활성성분이 포접된 포접체의 제조방법 및 이로써 제조된포접체의 용도
|
|
US20090143335A1
(en)
*
|
2007-10-29 |
2009-06-04 |
H. Lundbeck A/S |
Modified absorption formulation of gaboxadol
|
|
EP2291181B9
(en)
|
2008-04-18 |
2013-09-11 |
University College Dublin National University Of Ireland, Dublin |
Captodiamine for the treatment of depression symptoms
|
|
FR2935611B1
(fr)
|
2008-09-10 |
2010-10-15 |
Commissariat Energie Atomique |
Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
|
|
CN102549007B
(zh)
|
2009-08-13 |
2015-03-18 |
马瑞纳斯制药公司 |
3α-羟基,3β-甲基-5α-孕烷-20-酮(加奈索酮)的制备方法
|
|
AU2011207103B2
(en)
|
2010-01-21 |
2013-03-21 |
Drawbridge Pharmaceuticals Pty Ltd |
Anaesthetic formulation
|
|
DK2621282T3
(da)
|
2010-09-28 |
2020-05-04 |
Univ California |
Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
|
|
WO2012075286A2
(en)
*
|
2010-12-01 |
2012-06-07 |
The Regents Of The University Of California |
Intrapulmonary benzodiazepine for the treatment and prevention of seizures
|
|
CN107936076B
(zh)
|
2011-09-08 |
2021-10-15 |
萨奇治疗股份有限公司 |
神经活性类固醇、组合物、及其用途
|
|
ES2738526T3
(es)
|
2011-10-14 |
2020-01-23 |
Sage Therapeutics Inc |
Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
|
|
NZ773177A
(en)
|
2012-01-23 |
2022-09-30 |
Sage Therapeutics Inc |
Neuroactive steroid formulations and methods of treating cns disorders
|
|
WO2013188792A2
(en)
|
2012-06-15 |
2013-12-19 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
IL275725B
(en)
|
2012-08-21 |
2022-08-01 |
Sage Therapeutics Inc |
Treatment methods for epilepsy and status epilepticus
|
|
DK2925327T3
(da)
|
2012-11-30 |
2024-03-25 |
Univ California |
Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression
|
|
JP6542127B2
(ja)
|
2012-12-18 |
2019-07-10 |
ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ |
向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法
|
|
WO2014123909A1
(en)
|
2013-02-05 |
2014-08-14 |
University Of Washington Through Its Center For Commercialization |
Positive allosteric modulators of the gaba-a receptor in the treatment of autism
|
|
EP2956466A4
(en)
|
2013-02-15 |
2016-11-02 |
Univ Washington |
NEUROACTIVE ENANTIOMERS 15, 16 AND 17 SUBSTITUTED STEROIDS AS MODULATORS FOR GABA-A RECEPTORS
|
|
US9512170B2
(en)
|
2013-03-01 |
2016-12-06 |
Washington University |
Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
|
|
MX2015012437A
(es)
|
2013-03-13 |
2016-04-15 |
Sage Therapeutics Inc |
Esteroides neuroactivos, composiciones, y usos de los mismos.
|
|
AU2014243773B2
(en)
|
2013-03-13 |
2018-12-13 |
Sage Therapeutics, Inc. |
Neuroactive steroids and methods of use thereof
|
|
US9725481B2
(en)
|
2013-04-17 |
2017-08-08 |
Sage Therapeutics, Inc. |
19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
|
|
AU2014256229B2
(en)
|
2013-04-17 |
2018-10-04 |
Sage Therapeutics, Inc. |
19-nor C3,3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
|
|
RS60420B1
(sr)
|
2013-04-17 |
2020-07-31 |
Sage Therapeutics Inc |
19-nor neuroaktivni steroidi za metode lečenja
|
|
WO2014169836A1
(en)
|
2013-04-17 |
2014-10-23 |
Sage Therapeutics, Inc. |
19-nor neuroactive steroids and methods of use thereof
|
|
PL3021852T3
(pl)
|
2013-07-19 |
2021-07-05 |
Sage Therapeutics, Inc. |
Neuroaktywne steroidy, kompozycje i ich zastosowania
|
|
WO2015081170A2
(en)
|
2013-11-26 |
2015-06-04 |
Systamedic Inc. |
Ganaxolone derivatives for treatment of central nervous systems disorders
|
|
US9629853B2
(en)
*
|
2014-05-21 |
2017-04-25 |
Wisconsin Alumni Research Foundation |
Uses of ganaxolone
|
|
EP4144746A1
(en)
|
2014-05-29 |
2023-03-08 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions and uses thereof
|
|
SI3372229T1
(sl)
|
2014-06-06 |
2021-09-30 |
Ovid Therapeutics, Inc. |
Postopki za povečanje tonične inhibicije in zdravljenje angelman sindroma
|
|
US9802945B2
(en)
*
|
2014-06-12 |
2017-10-31 |
Pfizer Limited |
Imidazopyridazine derivatives as modulators of the GABAA receptor activity
|
|
GB2530001B
(en)
*
|
2014-06-17 |
2019-01-16 |
Gw Pharma Ltd |
Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
|
|
JOP20200195A1
(ar)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
سترويدات وتركيبات نشطة عصبياً، واستخداماتها
|
|
CN115381772A
(zh)
*
|
2015-02-06 |
2022-11-25 |
马瑞纳斯制药公司 |
静脉内加奈索酮制剂及其用途
|
|
BR112018000933A2
(pt)
|
2015-07-17 |
2018-09-04 |
Ovid Therapeutics Inc |
métodos de tratamento de um distúrbio de desenvolvimento
|
|
US20170348232A1
(en)
|
2016-06-07 |
2017-12-07 |
Ovid Therapeutics Inc. |
Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
|
|
US9682069B2
(en)
*
|
2015-07-17 |
2017-06-20 |
Ovid Therapeutics Inc |
Methods of treating Dravet syndrome
|
|
US9399034B1
(en)
|
2015-08-11 |
2016-07-26 |
Ovid Therapeutics Inc |
Methods of sedation during critical care treatment
|
|
WO2017027249A1
(en)
|
2015-08-11 |
2017-02-16 |
Ovid Therapeutics Inc. |
Methods of sedation and parenteral formulation for use during critical care treatment
|
|
PE20181332A1
(es)
|
2015-08-11 |
2018-08-20 |
Ovid Therapeutics Inc |
Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
|
|
US9351968B1
(en)
|
2015-09-09 |
2016-05-31 |
Ovid Therapeutics Inc |
Methods of treating developmental disorders using pipradrol
|
|
US10780099B2
(en)
|
2015-10-16 |
2020-09-22 |
Marinus Pharmaceuticals, Inc. |
Injectable neurosteroid formulations containing nanoparticles
|
|
WO2017070680A1
(en)
|
2015-10-22 |
2017-04-27 |
Cavion Llc |
Methods for treating angelman syndrome and related disorders
|
|
JP2019524816A
(ja)
*
|
2016-08-11 |
2019-09-05 |
オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
てんかん性障害の処置のための方法および組成物
|
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
|
AU2017363598A1
(en)
|
2016-11-22 |
2019-05-23 |
Ovid Therapeutics Inc. |
Methods of treating developmental disorders and/or seizure disorders with flupirtine
|
|
US10071083B2
(en)
|
2017-02-03 |
2018-09-11 |
Ovid Therapeutics Inc |
Use of gaboxadol in the treatment of tinnitus
|
|
EP3612186A1
(en)
|
2017-04-18 |
2020-02-26 |
Marinus Pharmaceuticals, Inc. |
Sustained release injectable neurosteroid formulations
|
|
WO2020106927A1
(en)
*
|
2018-11-21 |
2020-05-28 |
Certego Therapeutics |
Gaboxadol for reducing risk of suicide and rapid relief of depression
|